Miglitol Tablets

Miglitol is an oxynojirimycin derivative that delays the digestion of ingested sugars, resulting in only a slight increase in blood glucose concentration after a meal, thereby lowering blood glucose. Miglitol can reduce glycosylated hemoglobin levels in patients with type 2 diabetes. Systemic non-enzymatic protein glycosylation, as reflected by glycosylated hemoglobin levels, affects blood glucose concentrations over time.

Miglitol

This product is dark blue tablets.

Miglitol can be used alone as an adjunct to dietary control to improve blood sugar control in patients with non-insulin-dependent diabetes mellitus (NIDDM) who are poorly controlled by diet alone.

There is no fixed dose for diabetic patients to use miglitol or other hypoglycemic drugs. The dose of miglitol must be determined based on its efficacy and patient tolerance, but it must not exceed the maximum recommended dose (100 mg, 3 times/day). Initial dose: The recommended initial dose is 25 mg, taken before meals 3 times/day. Maintenance dose: 50 mg, 3 times/day. Maximum dose: 100 mg, 3 times/day.

Gastrointestinal reactions: Gastrointestinal symptoms are the most common adverse reactions of miglitol. The main manifestations are abdominal pain, diarrhea, and flatulence. The incidence of abdominal pain and diarrhea will be reduced with continued administration. Skin reactions: The incidence of rash when using miglitol is 4.3%, which is usually temporary. Abnormal laboratory indicators: The serum iron level of patients using miglitol is reduced, but most patients are temporary and are not accompanied by decreased hemoglobin and abnormalities in other hematological indicators.

1. Patients with diabetic ketoacidosis; 2. Patients with inflammatory bowel disease, colon ulcer, partial intestinal obstruction, and infectious intestinal obstruction; 3. Patients with chronic intestinal diseases accompanied by obvious gastrointestinal dysfunction, or further aggravated inflammatory bowel disease with intestinal bloating; 4. Patients who are allergic to the drug or its ingredients.

Precautions for children: The safety and effectiveness of this product for children have not been confirmed. Precautions for pregnancy and lactation: There is no data on safety tests for this product in pregnant women. Animal tests have been conducted, and no fertility damage or fetal toxicity was found in rats and rabbits at doses 3.4 times that of humans. The maximum dose in this study: 450 mg/kg for rats and 200 mg/kg for rabbits will increase toxicity to the mother and/or fetus. In addition, no adverse effects of this product on the survival, growth, development, behavior, and fertility of the next generation were found in perinatal and developmental toxicology studies in rats. Since animal tests cannot fully predict human responses, it can only be used in pregnant women when it is really necessary. The concentration of this product secreted into human milk is very small. When the mother is given a dose of 100 mg, only 0.02% is secreted into the breast milk. It is estimated that the dose received by breastfeeding infants is about 0.4% of the mother's dose. Although the amount of this product secreted into human milk is very low, it is still not recommended for use by breastfeeding women. Elderly precautions: Among the total number of cases in clinical studies conducted in the United States, 24% of the cases with confirmed safety were over 65 years old, and 3% were over 75 years old. The difference in effectiveness and safety between young and old people is not significant. A trial studied the changes in the pharmacokinetics of miglitol in elderly and young men (n=8 in each group), and found that there was no significant difference between the two groups at a dose of 100 mg, 3 times/day, for 3 consecutive days.

Sulfonylureas can cause hypoglycemia. If hypoglycemia occurs when miglitol is used in combination with sulfonylureas, the dosage of the drug should be adjusted promptly.

Keep in a dark place, sealed and protected from light

50mg

Temporarily 24 months

Weiao Pharmaceutical (Sichuan) Co., Ltd.

• Founded in:

  1998-01-08

• Address:

  No. 652, Tianfu East Road, Pengzhou City, Chengdu City, Sichuan Province

• Tax NO.:

  91510000620854656K

• Registered Funds:

  26 million yuan

• Website:

  Log in to view

• Email:

  Log in to view